Biomarker Partnering Terms and Agreements -





Publication date: September 2013 | Version: 6 | Pages: 987 

The Biomarker Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the biomarker partnering deals and agreements entered into by the worlds leading healthcare companies. 

  

  • Trends in biomarker partnering deals 
  • Biomarker partnering agreement structure 
  • Biomarker partnering contract documents 
  • Top biomarker deals by value 
  • Most active biomarker dealmakers 

  

The Biomarker Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the biomarker partnering deals and agreements entered into by the worlds leading healthcare companies. 

  

The report provides a detailed understanding and analysis of how and why companies enter biomarker partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors biomarker technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. 

  

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not. 

  

This report contains over 800 links to online copies of actual biomarker deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal. 

  

The initial chapters of this report provide an orientation of biomarker dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in biomarker dealmaking since 2007, including details of average headline, upfront, milestone and royalty terms. 

                     

Chapter 3 provides a review of the leading biomarker deals since 2007. Deals are listed by headline value, signed by bigpharma, most active bigpharma, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract. 

                             

Chapter 4 provides a comprehensive listing of the top 50 bigpharma companies with a brief summary followed by a comprehensive listing of biomarker deals as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand. 

  

Chapter 5 provides a comprehensive and detailed review of biomarker partnering deals signed and announced since January 2007, where a contract document is available in the public domain. The chapter is organized by stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. 

  

Chapter 6 provides a comprehensive and detailed review of biomarker partnering deals signed and announced since January 2007. The chapter is organized by specific diagnpstics technology type in focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. 

  

  

In addition, a comprehensive appendix is provided organized by biomarker partnering company A-Z , stage of development, deal type, therapy area, deal type definitions and biomarker partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. 

  

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of biomarker technologies and products. 

  

Biomarker Partnering Terms and Agreements is intended to provide the reader with an in-depth understanding and access to biomarker trends and structure of deals entered into by leading companies worldwide. 

  

Biomarker Partnering Terms and Agreements includes: 

  

  • Trends in biomarker dealmaking in the biopharma industry since 2007 
  • Analysis of biomarker deal structure 
  • Access to headline, upfront, milestone and royalty data 
  • Case studies of real-life biomarker deals 
  • Access to several biomarker contract documents 
  • The leading biomarker deals by value since 2007 
  • Most active biomarker dealmakers since 2007 
  • The leading biomarker partnering resources 

  

In Biomarker Partnering Terms and Agreements, the available contracts are listed by: 

  

  • Company A-Z 
  • Headline value 
  • Stage of development at signing 
  • Deal component type 
  • Specific therapy target 

  

Each deal title links via weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. 

  

The Biomarker Partnering Terms and Agreements report provides comprehensive access to available deals and contract documents for over 800 biomarker deals. Analyzing actual contract agreements allows assessment of the following: 

  

  • What are the precise biomarker rights granted or optioned? 
  • What is actually granted by the agreement to the partner company? 
  • What exclusivity is granted? 
  • What is the payment structure for the deal? 
  • How are sales and payments audited? 
  • What is the deal term? 
  • How are the key terms of the agreement defined? 
  • How are IPRs handled and owned? 
  • Who is responsible for commercialization? 
  • Who is responsible for development, supply, and manufacture? 
  • How is confidentiality and publication managed? 
  • How are disputes to be resolved? 
  • Under what conditions can the deal be terminated? 
  • What happens when there is a change of ownership? 
  • What sublicensing and subcontracting provisions have been agreed? 
  • Which boilerplate clauses does the company insist upon? 
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type? 
  • Which jurisdiction does the company insist upon for agreement law? 

Executive Summary 

 

Chapter 1 – Introduction 

 

Chapter 2 – Trends in biomarker dealmaking 

 

2.1. Introduction 

2.2. Biomarker partnering over the years 

2.3. Bigpharma biomarker dealmaking activity 

2.4. Most active biomarker dealmakers 

2.5. Biomarker partnering by deal type 

2.6. Biomarker partnering by disease type 

2.7. Biomarker partnering by stage of development 

2.8 Average deal terms for biomarkers 

2.8.1 Biomarker headline values 

2.8.2 Biomarker upfront payments 

2.8.3 Biomarker milestone payments 

2.8.4 Biomarker royalty rates 

  

Chapter 3 – Leading biomarker deals 

  

3.1. Introduction 

3.2. Top biomarker deals by value 

3.3. Top biomarker deals involving bigpharma 

  

Chapter 4 – Big pharma biomarker deals 

  

4.1. Introduction 

4.2. How to use big pharma biomarker partnering deals 

4.3. Big pharma biomarker partnering company profiles 

Abbott 

AstraZeneca 

Bayer 

Bayer 

Biogen Idec 

Boehringer Ingelheim 

Bristol-Myers Squibb 

Celgene 

Daiichi Sankyo 

Eisai 

Eli Lilly 

GlaxoSmithKline 

Johnson & Johnson 

Kyowa Hakko Kirin 

Merck & Co 

Merck KGaA 

Mitsubishi Tanabe 

Novartis 

Novartis Molecular Diagnostics 

Novo Nordisk 

Pfizer 

Purdue 

Roche 

Sanofi 

Servier 

Takeda 

Teva 

UCB 

  

Chapter 5 – Biomarker dealmaking directory 

  

5.1. Introduction 

5.2. By stage of development 

Discovery 

Marketed 

Phase I 

Phase II 

Preclinical 

5.3. By deal type 

Asset purchase 

Assignment 

Bigpharma outlicensing 

Co-development 

Collaborative R&D 

Contract service 

Co-promotion 

Development 

Distribution 

Equity purchase 

Grant 

Licensing 

Manufacturing 

Marketing 

Option 

Promotion 

Research 

Sub-license 

Supply 

Termination 

5.4. By therapy area 

Cardiovascular 

Central Nervous System 

Dental 

Genetic disorders 

Metabolic 

Oncology 

  

Chapter 6 – Biomarker dealmaking by technology type 

  

6.1. Introduction 

6.2. Deals by biomarker type 

Biomarkers 

  

Chapter 7 – Biomarker partnering resource center 

  

7.1. Online biomarker partnering 

7.2. Biomarker partnering events 

7.3. Further reading on biomarker dealmaking 

  

About Wildwood Ventures 

Current Partnering 

Current Agreements 

Recent titles from CurrentPartnering 

Order Form – Reports 

Order Form – Therapy Reports 

  

  

 Table of figures 

   

Figure 1: Biomarker partnering since 2007 

Figure 2: Big pharma – top 50 – biomarker deals 2007 to 2013 

Figure 3: Big pharma biomarker deal frequency – 2007 to 2013 

Figure 4: Active biomarker dealmaking activity– 2007 to 2013 

Figure 5: Biomarker partnering by deal type since 2007 

Figure 6: Biomarker partnering by disease type since 2007 

Figure 7: Biomarker partnering by oncology target since 2007 

Figure 8: Biomarker partnering by deal type since 2007 

Figure 9: Biomarker deals with a headline value 

Figure 10: Biomarker deal headline value distribution, US$million – 2007-2013– Discovery stage 

Figure 11: Biomarker deal headline value distribution, US$million – 2007-2013 – preclinical stage 

Figure 12: Biomarker deal headline value distribution, US$million – 2007-2013– phase I stage 

Figure 13: Biomarker deal headline value distribution, US$million – 2007-2013– phase II stage 

Figure 14: Biomarker deal headline value distribution, US$million – 2007-2013– phase III stage 

Figure 15: Biomarker deal headline value distribution, US$million – 2007-2013– regulatory stage 

Figure 16: Biomarker deal headline value distribution, US$million – 2007-2013– marketed stage 

Figure 17: Summary median headline value by stage of development, 2007-2013 

Figure 18: Biomarker deals with an upfront value 

Figure 19: Biomarker deal upfront value distribution, US$million – 2007-2013– discovery stage 

Figure 20: Biomarker deal upfront value distribution, US$million – 2007-2013– preclinical stage 

Figure 21: Biomarker deal upfront value distribution, US$million – 2007-2013– phase I stage 

Figure 22: Biomarker deal upfront value distribution, US$million – 2007-2013– phase II stage 

Figure 23: Biomarker deal upfront value distribution, US$million – 2007-2013– phase III stage 

Figure 24: Biomarker deal upfront value distribution, US$million – 2007-2013– regulatory stage 

Figure 25: Biomarker deal upfront value distribution, US$million – 2007-2013– marketed stage 

Figure 26: Summary median headline value by stage of development, 2007-2013 

Figure 27: Biomarker deals with a milestone value 

Figure 28: Biomarker deal milestone value distribution, US$million – 2007-2013– discovery stage 

Figure 29: Biomarker deal milestone value distribution, US$million – 2007-2013– preclinical stage 

Figure 30: Biomarker deal milestone value distribution, US$million – 2007-2013– phase I stage 

Figure 31: Biomarker deal milestone value distribution, US$million – 2007-2013– phase II stage 

Figure 32: Biomarker deal milestone value distribution, US$million – 2007-2013– phase III stage 

Figure 33: Biomarker deal milestone value distribution, US$million – 2007-2013– regulatory stage 

Figure 34: Biomarker deal milestone value distribution, US$million – 2007-2013– marketed stage 

Figure 35: Biomarker deals with a royalty rate value 

Figure 36: Biomarker deal royalty rate value distribution, US$million – 2007-2013– discovery stage 

Figure 37: Biomarker deal royalty rate value distribution, US$million – 2007-2013– preclinical stage 

Figure 38: Biomarker deal royalty rate value distribution, US$million – 2007-2013– phase I stage 

Figure 39: Biomarker deal royalty rate value distribution, US$million – 2007-2013– phase II stage 

Figure 40: Biomarker deal royalty rate value distribution, US$million – 2007-2013– phase III stage 

Figure 41: Biomarker deal royalty rate value distribution, US$million – 2007-2013– regulatory stage 

Figure 42: Biomarker deal royalty rate value distribution, US$million – 2007-2013– marketed stage 

Figure 43: Summary median headline value by stage of development, 2007-2013 

Figure 44: Top biomarker deals by value since 2007 

Figure 45: Top biomarker deals signed by bigpharma value since 2007 

Figure 46: Online partnering resources 

Figure 47: Forthcoming partnering events